SEC Tracker
Get the app
GYRE · XBRL financial data

Gyre Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (GYRE's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers32,04227,148*27,17225,22525,48827,872*22,05826,77130,56437,195*22,51929,105
Cost of goods and services sold1,1841,250*9797709581,177*8941,1511,6281,743*1,2272,209
Gross profit30,85825,898*26,19324,45524,53026,695*21,16425,62028,93635,452*——
Research and development41512,459*2,1823,3552,7753,712*3,0953,4252,3634,815*6,738—
Selling, general and administrative———————7,275———7,862
General and administrative2,4086,059*3,3983,4243,8235,464*4,9554,8294,3196,701*7,2207,867
Total operating expenses1,623172,056*18,12221,19320,29726,098*18,89123,44922,01140,750*31,87443,463
Operating income (loss)(1,623)(63,242)*8,0713,2624,233597*2,2732,1716,925118*(9,355)(14,363)
Other income (expense)(1,333)(237)*122(422)(598)(433)*107(145)727(2,194)*29(943)
Income tax expense (benefit)08,499*2,5461,4971,074203*9016621,6931,300*621(164)
Net income (loss)(1,576)(81,692)*9,9354,5382,856598*3,7341,5765,936(1,320)*(9,858)(14,270)
Earnings per share, basic USD per share(0.04)—0.090.040.010.01*0.030.000.04(0.01)*(0.10)(0.12)
Earnings per share, diluted USD per share(0.04)—0.030.010.010.01*0.000.000.03(0.01)*(0.10)(0.12)
Weighted average shares, basic thousands of shares37,977—83,26685,50285,64485,952*86,42189,11990,85090,923*91,317100,638
Weighted average shares, diluted thousands of shares37,977—102,594104,325102,64099,639*101,971102,702103,972104,045*91,345100,638

Balance sheet

CSV

Fiscal quarters (GYRE's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents2,22833,50929,78516,09715,86611,81315,04536,49140,40237,07037,50143,287
Short-term investments——7,5679,0039,22614,85814,84617,87419,64715,35512,30714,058
Accounts receivable—15,163———19,58920,15024,62925,87731,07822,76327,760
Inventory—4,2814,9395,6356,3796,3377,8788,861—10,17111,35211,428
Prepaid and other current assets—————2,6258,1612,7012,8739,6133,7627,601
Total current assets5,13257,22162,72353,51954,80964,78668,44891,28598,576102,36991,732122,072
Property and equipment, net—23,28823,56423,67224,44223,88023,51823,40123,60823,59923,57227,284
Right-of-use asset—4893592,0971,9841,8181,6001,5001,3001,1312,4003,279
Total assets9,964116,539122,010120,929125,240125,406129,790152,646159,384166,132162,015199,255
Accounts payable158355330271303108122715561242651,236
Total current liabilities1,78320,04719,48615,57414,71619,51618,99116,92015,91318,28619,78828,663
Lease liability, non-current—1991751,2971,101885780771539303722,033
Total liabilities6,44738,06533,23927,58326,76627,00425,48823,20321,96923,85025,03034,336
Accumulated deficit(414,724)(85,538)(78,006)(74,478)(73,354)(73,453)(70,755)(70,313)(66,703)(68,426)(77,667)(137,962)
Total stockholders' equity3,517(15,828)56,64060,35163,17963,31968,12392,026101,920106,031101,309107,928
Total liabilities and equity9,964116,539122,010120,929125,240125,406129,790152,646159,384166,132162,015199,255
Common shares outstanding (cover page) thousands of shares37,97885,42385,51093,42493,52193,61293,75896,31396,33396,96497,028111,510

Cash flows

CSV

Fiscal quarters (GYRE's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(1,576)(81,692)*9,9354,5382,856598*3,7341,5765,936(1,320)*(9,858)(14,270)
Stock-based compensation98*6,884*1116*237*567*507906*1,147*4,597*2,5832,075*
Depreciation and amortization0*1,070*415228*445*461*535641*649*656*6721,483*
Net cash from operating activities(3,217)*year only2,884(5,493)*1,726*(2,758)*(129)2,088*4,676*(5,625)*3,180(16,728)*
Purchases of property and equipment1,974*2,324*2311,456*693*(65)*122256*668*144*178262*
Net cash from investing activities0*(24,966)*(7,220)(8,273)*(2,387)*(2,004)*1,967(3,042)*(1,247)*1,848*(3,055)9,757*
Proceeds from issuing common stock—————year only50922,491*————
Proceeds from issuing equity—year only——————————
Dividends paid1,500*———————————
Net cash from financing activities(1,478)*15,240*658156*324*964*1,34422,351*365*318*21(8)*
Net change in cash(4,695)*27,772*(3,724)(13,688)*(231)*(4,053)*3,23221,446*3,911*(3,332)*431(6,336)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Gyre Therapeutics43,28729,105(16,728)*111.5M3.4 quarters 10-QJun 30, 2026
Volitionrx2,800399(5,160)*13.6M0.5 quarters 10-QJun 30, 2026
Oncolytics Biotech4,115not reported(8,138)*127.5M0.5 quarters 10-QJun 30, 2026
Seres Therapeutics15,594736(22,394)*9.9M0.7 quarters 10-QJun 30, 2026
Macrogenics113,90732,832(40,748)*63.7M2.8 quarters 10-QJun 30, 2026
Inovio Pharmaceuticals31,5260(18,047)*103.4M2.0 quarters 10-QJun 30, 2026
XBiotech109,528not reported(4,515)*30.5M24.3 quarters 10-QJun 30, 2026
Oramed Pharmaceuticals15,245not reported(200)*41.6M80.5 quarters 10-QJun 30, 2026
Corbus Pharmaceuticals Holdings23,370not reported(29,626)*19.3M4.0 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.